
# Corporate Presentation

## APR Applied Pharma Research s.a.

April 2021

**Developer of smart, differentiated products in niche therapeutic areas on a global basis**

**Swiss pharma company with a 25+ year track record of leveraging patented drug delivery technologies**

## What we do:

Identify, develop and commercialize known molecules engineered with drug delivery systems in niche diseases on a global basis

Use our core R&D competences to offer first-in-class contract development services to third party innovators


## Vision: We Share Care

We want to make a real difference in the life of people living and dealing with debilitating diseases

## Risk mitigated approach to R&D: making known medicines better

### Proprietary Products

**Identification, development and commercialization of patented products in niche indications**

Focus in selected therapeutic areas on a global basis.

**A** — **2 core Technologies**

PHYSIOMIMIC technology

TEHCLO Applied NanoScience

**B** — **2 main Areas**

- Inherited Metabolic Diseases
- Niche Disorders

**C** — **2 Commercial Strategies**

1. **Direct Sales in EU and Distribution in RoW for Metabolic Products**
2. **Royalty bearing Licensing for all other Products**

### Third Party Products

**Incubator and an accelerator of third party's innovation**.

APR offers its core competencies in the development of third part's ideas and products on a flexible contract basis.

APPLIED PHARMA RESEARCH

**We do not simply execute what clients are asking for…**

**… we listen to them**

**and we do our best to enable and materialize innovations**


**Combining technical excellence in formulation development with deep expertise in regulatory path across multiple categories (Rx, OTC, MD, FS) in a lean organization**

# recent key milestones

**Q1/2021**

**SENTINOX** — COVID-19 and other airborne viruses

Received Marketing Authorization in Europe as Class III MD

**Q4/2020**

SetoFilm — CINV, RINV and PONV

NORGINE acquires SetoFilm for EU, Australia and New Zealand

**Q2/2020**

GOLIKE — Phenylketonuria (PKU)

Launch of Shake & Drink on the International PKU Day (June 28)

**Q1/2020**

APR-OD031 — Phenylketonuria (PKU)

FDA — US FDA granted Orphan Drug Designation

**Q4/2019**

APR-TD011 — Epidermolysis Bullosa (EB)

FDA — US FDA granted Orphan Drug Designation

# Product Portfolio & Pipeline

## Key Therapeutic Areas / Products

| Product | Indication | Preclinical | Clinical | Reg. | Market | Notes |
|---|---|---|---|---|---|---|
| **Inherited Metabolic Recessive Disorders** | | | | | | |
| GOLIKE | Phenylketonuria (PKU) | | | | | First FSMP engineered with delivery technology |
| **APR-OM032** | Tyrosinemia (TYR) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OM033** | Maple Syrup Urine Disroder (MSUD) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OM034** | Homositinuria (HCU) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OD031** | Phenylketonuria (PKU) | | | | | ODD granted by FDA in Q1/2020 |
| **Niche Disorders** | | | | | | |
| NEXODYN | Chronic Wounds | | | | | Chronic Wounds |
| SetoFilm Ondissolve ODF | CINV, RINV and PONV | | | | | First Rx Product approved with ODF Technology |
| SENTINOX | Infectious Diseases (COVID-19) | | | | | First Nasal Spray indicated for SARS-CoV-2 |
| **APR-TM011** | Skin Toxicities in cancer Therapies | | | | | First Rx Product with a specific labeled indication |
| **APR-TD011** | Epidermolysis Bullosa (EB) | | | | | ODD granted by FDA in Q4/2019 |
| **APR-TD012** | Haley Haley Disease (HHD) | | | | | |
| **APR-TD013** | Buruli Ulcer (BU) | | | | | Eligible for FDA Voucher (Working with WHO) |

## Cash Cow Products

| Product | Indication | Preclinical | Clinical | Reg. | Market | Notes |
|---|---|---|---|---|---|---|
| **Other Therapeutic Areas** | | | | | | |
| CAMBIA Voltfast | Acute Migraine Attacks in Adults | | | | | First and only NSAID cleared by FDA for Migraine |
| eminocs | Acute Pain | | | | | |
| Voltadol | Local Pain and Strains | | | | | |
| HALYKOO | Pediatric Line | | | | | |
| SwitzAGE | Food Supplement Line | | | | | |

# Inherited Metabolic Diseases

## Phenylketonuria (PKU)

| | | | | | | |
|---|---|---|---|---|---|---|
| GOLIKE | Phenylketonuria (PKU) | | | | | First FSMP engineered with a drug delivery technology |
| **APR-OM032** | Tyrosinemia (TYR) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OM033** | Maple Syrup Urine Disroder (MSUD) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OM034** | Homocitinuria (HCU) | | | | | Expected Launch as FSMP in 2023/2024 |
| **APR-OD031** | Phenylketonuria (PKU) | | | | | Orphan Drug Designation (ODD) granted by FDA in Q12020 |

PHYSIOMIMIC™ technology

**Leverage a patented drug delivery technology to develop and commercialize differentiated products in the most prevalent, rare, inherited metabolic diseases**

The first and only technology able to control and prolong release of multiple active ingredients (19) simultaneously

**Building a global presence with a combination of direct S&M and selected partners**

| Country | Partner | Notes |
|---|---|---|
| | APR APPLIED PHARMA RESEARCH | **Direct S&M** |
| | APR APPLIED PHARMA RESEARCH | **Direct S&M** |
| | lifediet | **Launched Q4/2019** |
| | RENDON EUROPE | **Launch Q4/2020** |
| | Synchrony Pharma | **Launch Q4/2020** |
| | 以岭万洲国际制药有限公司 YILING PHARMACEUTICAL LTD | **Launch Q2/2022** |
| | MDM PHARMA BRASIL | **Launch Q2/2021** |
| | TrueMed | **Launch Q2/2021** |
| | **PharmacarePlus** | **Launch Q4/2020** |
| | | |

**Enter the ~$ 1,0 billion inherited, metabolic disease market starting from the ~$ 0,5 billion PKU segment**




More than 350,000 PKU patients across key geographies. Patients concentrated in small number of PKU centers that can be targeted with a small salesforce

# Phenylketonuria, Tyrosinemia (cont.)

GOLIKE

**The first FSMP* engineered with a drug delivery technology: a differentiated product offering an improved metabolic management and a better compliance**

* FSMP: Food for Special Medical Purposes

## Unique positioning


## Complete family of products covering main age groups and individual habits


## Clear LCM Strategy through 2024

| | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Master SKUs | PKU GOLIKE sachets | GOLIKE Shake & Drink | PKU GOLIKE sachets and GOLIKE Shake & Drink to be merged in a unique SKU, Ready to Drink | | PKU GOLIKE Ready to drink | |
| Complementary SKUs | | | PKU GOLIKE Krunch | PKU GOLIKE Bar | PKU GOLIKE Krunch new flavors | PKU GOLIKE Bar new flavors |
| IEM SKUs | | | | | | TYR GOLIKE Ready to drink |

## Our distribution Partners benefit from APR corporate support:

| | |
|---|---|
| **Marketing Support** | Positioning, handout materials, videos |
| **Training Sale Force** | Training Sessions and Training Materials of the local Sale Force |
| **Medical Affairs** | Clinical Studies, Publications, local events |
| **Advisory Board** | Organization of local advisory boards with KOLs |
| **R&D** | Development of follow on and LCM products |

## A new Product to block COVID-19

**An additional protection to block airborne virus / bacterial infections and transmission (including SARS-CoV-2)**

- **SENTINOX is a ready to market, Class III Medical Device approved in EU** on February 16th 2021.
- **SENTINOX is an intranasal spray** containing a well-known, safe and effective antiviral which can block transmission of the SARS-CoV-2 virus (including its mutations) from the respiratory tract and limit or reduce the effects of COVID-19.
- **SENTINOX eliminates the virus directly at the site** where the disease begins - the upper respiratory tract. Thanks to its safety profile, Sentinox can be marketed as a precautionary measure to a wide array of patients and consumers.


- **SENTINOX is a long-term commercial opportunity**: it can be initially commercialized as prophylactic/preventive measure against COVID-19 capitalizing on the strong approved claims. This positioning will allow product extension in the prevention of other respiratory viruses, extending the product lifecycle far and beyond COVID-19.

## Approved Claims

APR obtained the following approved main labelled claims:

- **Prophylaxis/Prevention Claims**: reducing the risk of infections caused by bacteria and viruses, including SARS-CoV-2 (etiologic agent at the basis of the pandemic COVID-19), by lowering the nasal microbial load
- **Symptomatic Claims**: symptomatic nasal care (to ease nasal symptoms, e.g. nasal congestion, typical of upper respiratory conditions such as cold, flu, sinusitis or rhinitis)
- **General Claim**: nasal care in case of minor lesions/alteration of the nasal mucosa (e.g. creates an ideal environment for an optimized resolution of irritation and lesions)




**Daily new confirmed COVID-19 cases**

# Acute and Chronic Wounds

AcidOxidizing Solution (AOS) NEXODYN THE WOUND CLOSURE CLEANSER

## Nexodyn is a sprayable HClO solution offering clinically proven efficacy with an excellent safety profile

**15** million
Estimated number of people who will develop a stalled wound during their lifetime in Europe and the US combined

**$41** billion
**Pressure ulcer global expenditure in 2015**
Average annual cost per patient
**$15,400**

**$52** billion
**Diabetic foot ulcer global expenditure in 2015**
Average annual cost per patient
**$44,200**

**$50** billion
**Venous leg ulcer global expenditure in 2015**
Average annual cost per patient
**$11,000**

## Pathology Overview of Non-Healing Wounds

- Non-healing wounds may persist for months due to the build up of bioburden and biofilm and pro-inflammatory mediators




- Non-healing wounds are a globally escalating problem primarily driven by an aging population and changes in lifestyle conditions that directly result in increased diabetic wounds and pressure ulcers

## Pharmaco/Economic Study in Italy

### 61% Cost Reduction vs. SOC[1]




€573.00*
Total Cost Savings
*Includes the cost of Nexodyn® AOS

Wound episode total cost: €933

## Nexodyn is supported by a wealth of clinical data


1. Internal APR data
2. Iacopini E. The Use of a Novel Super-Oxidized Solution on Top of Standard Treatment in the Home Care Management of Postsurgical Lesions of the Diabetic Foot Reduces Reinfections and Shortens Healing Time, Int J Low Extrem Wounds; 2018 Oct

**A wealth of clinical evidence consistently supports Nexodyn's material impact on wound-related economic burden through accelerated wound closure, reduced infection rates, and reduced wound-associated pain**

# Acute and Chronic Wounds (cont.)

AcidOxidizing Solution (AOS) NEXODYN THE WOUND CLOSURE CLEANSER

## Nexodyn® AOS is proven to restart healing in stalled wounds, creating the ideal microenvironment to sustain the physiological healing process


- Strong antimicrobial properties (against viruses and bacteria)
- Anti-inflammatory activity (irreversibly inhibits MMP-2 and MMP-9)
- Ability to remove Bio-film

### Superiority vs. Other Cleansers




## A Wealth of Clinical Evidence and Publications showing Nexodyn's Superiority vs. Standard of Care

### Faster Healing Time vs. SOC




Half the time for complete healing vs. standard treatment

*p<0.01 vs. saline

### Infection Reduction vs. Baseline




Median infection score decreases significantly in the first 2 weeks without use of other antimicrobial products

*p<0.0001; Friedman test

### Wound Reduction vs. Baseline




37% of stalled lesions fully healed at the end of the clinical observation

*p<0.0001; Friedman test

### Pain Reduction vs. Baseline




Wound-associated pain decreases rapidly during the observation period (median VAS = 1 at day 35)

*p<0.0001; Friedman test

# CINV, RINV and PONV

SetoFilm Zuplenz Ondissolve ODF

**First and only Ondansetron containing product approved as Oral Dispersible Film for the treatment of Chemotherapy and Radiotherapy induced nausea and vomiting (CINV, RINV and PONV) in children and adults.**

SetoFilm Gé

Seul ondansétron en film orodispersible

**FDA approved as 505(b)2 NDA**

- **Building a global presence with long term commercial partners**
- **Expand in still available territories**

| Country | Partner | Notes |
|---|---|---|
| | NORGINE | Launched in 2013 |
| | NORGINE | Launched in 2013 |
| | NORGINE | Launched in 2013 |
| | NORGINE | Launched in 2013 |
| | Takeda | Launched in 2015 |
| | mt | Partnership AQST |
| | Gador | Under registration |
| | glenmark | Under registration |
| | LaVasta PHARMA | Under registration |

**Approved for children (in EU only) with CINV and RINV thanks to the delivery system which avoid suffocation**


## How ODF Works

- ODF is an innovative oral dosage form that combines the convenience of a liquid with the stability and dosing accuracy of a tablet
- After the film is administered, the active ingredient is swallowed with saliva and is metabolized by the liver
- Polymers are used as film formers to hold the API and excipients in place while specific techniques are used to ensure that the API is uniformly distributed throughout the film

# Skin reactions/lesions in Cancer Patients

## APR-TM011

**First Class III Medical Device approved in EU in the prevention and treatment of skin lesions in cancer patients due to anti-EGFR inhibitors**

### Papulopustular Skin Rushes/Lesions

Induced by anti-EGFR Inhibitors (MABs and TKIs)



*~200K Patients/Year**

**Signs and Symptoms**

Lesions usually develop within the first weeks of treatment and can last as late as 6 weeks after EGFR inhibitors have commenced.
Lesions are generally painful and itching

**Prevalence and Incidence**

With EGFR MABs ranges 45%–100% of patients
(Cetuximab 88%–90%, Panitumumab 100%)

With EGFR TKIs ranges 47%–71% of patients
(Erlotinib 60–99%, Afatinib 81–100%)

### Radiodermatitis

Induced by cancer radiation therapy



*~1,7 Mio Patients/Year**

**Signs and Symptoms**

They range from Erythema (Grade 1) to ulcerations and necrosis (Grade 4)
Lesions are generally painful and itching

**Prevalence and Incidence**

In 2018, ~18,1 Mio newly diagnosed cancer patients
Radiotherapy recommended in 50% of patients

* *Top 5 European Countries*

# Skin reactions/lesions in Cancer Patients (cont.)

## Product Overview

- APR-TM011 has the potential to be the first product indicated for the prevention and treatment of skin rashes associated with anti-EGFR mAb treatments
  - Result in substantial improvement in the quality of life of cancer patients
  - Positively impact survival rates due to improved compliance and adherence to the mAb treatment regimen

## Clinical Study & Results

- **Clinical Study:** 15 cancer patients (10 men / 5 women) were treated for 3 months between October 2017 and March 2018 with cetuximab (Erbitux) and APR-TM011 was applied daily in conjunction with lenitive creams
- **Clinical Results**:
  - No patients developed any adverse skin events and 100% of patients completed their cancer treatment regimen

## Wound Area Reduction




- In the 15 patients the widths measured ranged from 5 cm to 22 cm, while the lengths from 10 cm to 40 cm. The patient with the largest injured area was 22 cm x 40 cm lesion.
- **Results**: 93.3% of patients had a greater than 90% reduction in the area while 1 patient had a reduction of 88.9%

## Development Pathway and Commercial Strategy

- **APR-TM011 is approved as a Class III Medical Device in EU for the prevention and treatment of skin rashes associated with anti-EGFR mAb treatments**
- APR is pursuing a label revision / extension for APR-TM011 in the EU based on the product's current clinical trial evidences
  - The label revision / extension will include skin reactions in cancer patients being treated with anti-EGFR mAbs
- APR-TM011 is patent protected until 2028
  - APR is in the process of filing an additional patent in the US claiming this additional indication, which could extend exclusivity well beyond 2028.

# Orphan designated early stage products

**The US FDA granted to APR the Orphan Drug Status to the following early stage programs in two different rare disease settings**

## APR-TD011 (Epidermolysis Bullosa)

- EB is a group of rare, genetic, life-threatening connective tissue disorders characterized by skin blistering throughout the body and risk of severe impact to internal organs
  - It is estimated that EB affects ~250,000 EB patients worldwide, with ~30,000 patients in the EU and ~20,000 patients in the US
- There are three main types of EB: EB simplex (EBS), dystrophic EB (DEB) and junctional EB (JEB)
  - DEB and JEB are the most severe forms of EB representing about ~30% of all EB patients and are life threatening conditions

### Product Overview

- APR-TD011 is a HClO sprayable solution that combines a strong antimicrobial action with anti-inflammatory properties and has the potential to become one of the first products ever approved for EB
- In a preliminary proof of concept clinical trial, EB patient administered with APR-TD011 has demonstrated improvement in skin blistering and tissue repairing in just two weeks of treatment







## APR-OD031 (Phenylketonuria)

- Majority of the US PKU population diagnosed through Newborn Screening has no access (~46% or ~6,900 patients) or limited access (~33% or ~5,000 patients) to the only available treatment options (FSMPs)
- Currently available FSMPs show sub-optimal outcome and related side effects despite they represent up to 80%-85% of the daily protein intake for the entire life of majority of PKU patients

### Strong Evidences of APR-OD031

APR-OD031 shows significant reduction of Blood Urea Nitrogen (BUN) indicating a strong reduction of catabolic events in favor of anabolic processes

**Catabolic Event Reduction**




APR-OD031 shows significant reduction of PHE fluctuations over time indicating a better metabolic management

**PHE Fluctuation Reduction**



# Other Therapeutic Areas

## Main royalty generating products

| | | | | | | |
|---|---|---|---|---|---|---|
| CAMBIA / Voltfast | Acute Migraine Attacks in Adults | [redacted] | [redacted] | [redacted] | [redacted] | F |
| eminocs | Acute Pain | [redacted] | [redacted] | [redacted] | [redacted] | |
| Voltadol | Local Pain and Strains | [redacted] | [redacted] | [redacted] | [redacted] | |
| HALYKOO | Pediatric Line | [redacted] | [redacted] | [redacted] | [redacted] | |
| SwitzAGE | Food Supplement Line | [redacted] | [redacted] | [redacted] | [redacted] | |

### CAMBIA

Diclofenac Potassium for Oral Solution

- The first and only FDA approved NSAID for the treatment of acute migraine attacks in adults (through 505(b)2 NDA)
  - Patent exclusivity until January 1st 2023
  - Working on Life Cycle Management to extend exclusivity until 2026
  - ~$ 45 Mio/year in Net Sales in USA and Canada
- Main Partners

ASSERTIO

NUVO

### Voltfast

- Fast Acting, patent protected acute pain medication approved in various countries a Abbreviated New Drug Application
  - Marketed by Novartis in several countries worldwide
  - Patent exclusivity and royalty stream secured until 2024
  - ~$ 35 Mio/year in Net Sales in Novartis territories
- Main Partners

NOVARTIS

### eminocs

Diclofenac potassico

- First Oral Drop formulation of Diclofenac for Acute Pain and Migraine
- Marketed in Italy and available for licensing in other territories
- Main Partners

shedir pharma group

### Voltadol

- First matrix pain patch marketed by GSK in several countries of EU
  - Indicated for local pain
  - ~$ 20 Mio/year in Net Sales in GSK territories
- Main Partners

gsk GlaxoSmithKline

# OTC baby healthcare line of products

HALYKOO
RESEARCH WITH BABIES IN MIND

www.halykoo.com

The first and only OTC baby healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children's growth with smart and innovative delivery systems intended to simplify their use for parents and reduce the hassle for babies.

- 27 Products developed and approved in EU in the 4 categories
- 4 Products close to completion
- 7 product under regulatory change
- **Divestment and monetization process on going.**




# Overview of Partnered Products

| DDS | Technology Overview/Benefit | Product/Brand | Product Overview/Exclusivity | Main Partners |
|---|---|---|---|---|
| **Dynamic Buffering Technology** | ▪ Immediate Release Technology offering an increased rate of drug absorption and faster peak plasma levels<br>▪ Secures a fast and sustained pain relief in different pain settings | CAMBIA Diclofenac Potassium for Oral Solution | ▪ First and still the only NSAID approved by FDA for acute migraine attacks in adults<br>▪ Exclusivity until 2023/2026 | ASSERTIO NUVO |
| | | Voltfast diclofenac | ▪ Acute pain (rescue Rx medication)<br>▪ Exclusivity until 2024 | NOVARTIS |
| | | Диклрепид 50мг, ITAMIFAST, Dicloreumdol, Inflamac 50 rapid | ▪ Acute local pain (OTC)<br>▪ Exclusivity until 2026 | Dr.Reddy's, ZENTIVA, teva, fidia farmaceutici |
| **Matrix Patch Technology** | ▪ Transdermal patch technology for absorption of active substance through the skin<br>▪ Allows better adhesivity and flexibility especially on joints | Voltadol | ▪ Acute local pain (OTC)<br>▪ Patent protection until 2027 | gsk GlaxoSmithKline |
| | |   | ▪ Cough & Cold (OTC)<br>▪ Patent protection until 2027 | Pediapharm, P.S.A. FARMACEUTICA |
| **Oral Dispersible Film Technology** | ▪ Film-based technology that can be tailored for three delivery sites : buccal, sublingual and lingual<br>▪ Allows for improved drug absorption combined with a better patient compliance | Zuplenz (ondansetron) oral soluble film<br>SetoFilm Orodispersible film Ondansetron<br>Ondissolve ODF Ondansetron Orally Disintegrating Film Ondansétron film à désintégration orale | ▪ Chemotherapy Induced Nausea and Vomiting (CINV)<br>▪ Radiotherapy Induced Nausea and Vomiting (RINV)<br>▪ Post Operative Induced Nausea and Vomiting (PONV)<br>▪ Exclusivity through 2031 | MIDATECH PHARMA, NORGINE, Takeda |

# Structure, Governance and Locations

**APR is a private corporation registered and operating under Swiss Law with two institutional investors as major shareholders**

## Management Team

Experienced and results driven Management Team with proven leadership

**Paolo Galfetti**
Chief Executive Officer & co-founder

**Giorgio Reiner**
Corporate Director R&D & co-founder

**Giulia Recalcati**
Corporate Director Finance

**Alessia Bettinelli**
Corporate Director Marketing & Sales Metabolic

**Marco Marotta**
Corporate Director Partnering and BD

**Sara Mazzuoccolo**
Corporate Director Operations & Sales

## Board of Directors

**Thomas Rinderknecht**
Chairman of the Board
Biotech advisor/investor, lawyer

**Enrico Braglia**
Non-executive member
Biotech investor and fund manager

**Alexander Asam**
Non-executive member
Biotech investment fund manager

**Jacques Gonella**
Independent member
Serial entrepreneur

**Paolo Galfetti**
Executive member
CEO

**Giorgio Reiner**
Executive member
Corporate Director R&D

## Locations

APR is headquartered in Balerna, Switzerland with its own Sale & Marketing subsidiaries in Rome (Italy) and Offenbach (Germany)



## People

# R&D Capabilities and Organization

## Track Record

**Developed 5 unique, proprietary technology platforms and leveraged these platforms to develop over 50 products over time in multiple categories**

### Proven, Long-Standing R&D Expertise

- **25+ years of R&D experience in developing innovative products**
  - Managing product development from formulation development through the regulatory approval process
  - Expertise extends across multiple categories (Rx, OTC, nutraceuticals, dermo-cosmetic and medical device)
- **R&D team manages all aspects of product development**
  - Lean and flexible in-house team of professionals with deep industry experience coupled with an extensive network of clinical advisors and Key Opinion Leaders
  - Leverage outsourced providers for functions such as commercial manufacturing and clinical trial management
- **Core competencies in oral and topical dosage forms**
  - Technical know-how to develop tablets, granules, buccal and sublingual oral films, gels, creams, ointments, liquids, and sprays
- **Current infrastructure consists of in-house labs working under strict applicable guidelines**
- **10-member Advisory Board comprising international experts in genetic metabolic diseases consults with APR throughout the R&D process**
  - APR also leverages the expertise of 3 board members who are recognized pioneers and leaders in the drug delivery market

### R&D Organization




(1) Director of R&D also serves as Head of Intellectual Property

### Selected Contract Dev. Clients

ALFASIGMA, TONIX PHARMACEUTICALS, SANOFI, NOVARTIS, Reckitt Benckiser, Zambon, Siegfried

APR stands as a trusted formulator and developer validated by the breadth and quality of its contract development partners and products developed over time under flexible fee for service agreements.

# Contract Service Provider

**TURNING YOUR IDEAS INTO PRODUCTS**

## Wide range of Added Value Services

- Intellectual Property
- Technical Development
- R&D and QC Analytical
- Industrial Upscaling
- Regulatory Compliance
- Project Management

## Across multiple categories

- Rx Drugs
- OTC Drugs
- Medical Device
- Medical Food
- Nutraceuticals
- Cosmetics

## Adding Value to your Projects and Development Strategy


| | |
|---|---|
| **Intellectual Property** | ▪ IP proved experience to maximize your Innovation value<br>▪ Revamp an old or weak Patent to a wider and more effective one |
| **Technical Development** | ▪ Catch the brief, figure out the Product beyond an Idea<br>▪ Feasibility study, Gap Analysis, Project management<br>▪ Formulation, delivery system, analytical methods, manufacturing process<br>▪ Prototypes manufacturing and pre-clinical studies, target product profile, Tech Transfer from lab scale to industrial manufacturing, to the Market |
| **Control** | ▪ Set up, Validation and Transfer of Analytical Methods<br>▪ Product quality profile and Stability Studies<br>▪ R&D and GMP Contract Analytical Services |
| **Small Lab batches manufacture** | ▪ Design of Experiment – Quality by Design Approach<br>▪ Proof of Concept batches for feasibility studies and patent scope<br>▪ Small lab batches to assess raw materials, formulation or process changes<br>▪ Pre-clinical batches manufacturing |
| **Compliance Innovation Creativity** | ▪ Reformulation, repositioning, repurposing and new delivery<br>▪ Improvement of Product Design, User Experience and Usability<br>▪ Technical and regulatory know how in different Healthcare areas<br>▪ Multitasking Approach: formulative, analytical, industrial, regulatory |
| **Finding viable Solutions** | ▪ Heuristics experience, out of the box mindset<br>▪ An extensive Network of best in class and trusted Partners<br>▪ We make it happen and keep it simple |

# Headquarters and Employees

## Headquarters

| | |
|---|---|
| **Location** |  <br>Via Giuseppe Corti 5<br>Balerna, Switzerland |
| **Key Functions** | ▪ Executive<br>▪ Research and Development<br>▪ Business Development and Partnering<br>▪ Sales and Marketing<br>▪ Medical Affairs<br>▪ Finance<br>▪ Logistics |
| **Own / Lease** | Leased |
| **Square Feet** | ~15,000 sf |
| **Employees (FTEs)** | 34 FTEs at Corporate Headquarters<br>8 FTEs at Subsidiary Level<br>(4 FTEs in APR DE and 4 FTEs in APR IT) |

### CERTIFICATIONS

APR is a registered pharmaceutical company in Switzerland, licensed and regularly inspected by the local Health Authority (SwissMedic). In particular, APR is a licensed GDP (Good Distribution Practices) and GLP (Good Laboratory Practices) company.

In addition, APR owns the 13485 Certification issued by TUV for Medical Devices.

### GOVERNANCE

The Company has adopted Corporate Governance Guidelines in order to provide the framework for the governance of APR and all the companies belonging to the APR Group.

- Corporate Governance Guidelines
- Code of Ethics
- Data Protection Policy (Privacy)
- Guideline on interactions with Healthcare Professionals (HCPs)
- Compliance Board

**Paolo Galfetti**
CEO
email: paolo.galfetti@apr.ch

**APR Applied Pharma Research s.a.**
Via Corti, 5 - 6828 Balerna
Switzerland
Ph. +41 91 695 70 20

www.apr.ch